Use of machine learning techniques to identify risk factors for RV failure in LVAD patients

Nair, Nandini

doi:10.3389/fcvm.2022.848789

Cited by 3 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This should be evaluated with regular echocardiograms and cautious volume optimization with LVAD speed adjustments, diuresis, or ultrafiltration. Pulmonary hypertension should be treated with phosphodiesterase-5 inhibitors or inhaled nitric oxide [30].…”

Section: Post-operative Care and Monitoringmentioning

confidence: 99%

LVAD Continuing Care: A Comprehensive Guide to Long-Term Support and Management

Sobieraj,

Best,

Ahmed

et al. 2024

Cardiology and Cardiovascular Medicine

View full text Add to dashboard Cite

Heart failure is a growing pandemic with a rising societal burden. Heart failure affects 3.6 million people in Europe and 5 million in the United States annually. The United States alone spends 30.7 billion annually managing heart failure, and that number is expected to eclipse 70 billion by 2030. Many people are not orthotopic heart transplant candidates, and many who are may not live long enough to receive a transplant. As a result, durable left ventricular assist devices (LVAD) have become both a bridging therapy and a destination therapy, necessitating a robust continuing care system. LVAD programs are expanding to fill this need. This chapter aims to cover the spectrum of LVAD continuing care from initial implantation to the outpatient clinic. This chapter will cover essential care practices for maintaining LVAD function, including driveline care, battery management, and alarm response/tracking. Troubleshooting the common issues and complications patients might experience, such as low flow alarms, bleeding, infection, and right heart failure. Emphasize the importance of the primary caregiver’s involvement and how to prepare them by providing resources for education, training, and ongoing support. Lastly, it will cover ethical concerns and the role of palliative care in the process.

show abstract

Section: Post-operative Care and Monitoringmentioning

confidence: 99%

LVAD Continuing Care: A Comprehensive Guide to Long-Term Support and Management

Sobieraj,

Best,

Ahmed

et al. 2024

Cardiology and Cardiovascular Medicine

View full text Add to dashboard Cite

show abstract

“…Determining which LVAD patient requires mechanical RV support remains challenging, and the decision should be the result of a multidisciplinary team approach, taking into consideration detailed clinical, advanced echocardiographic, and hemodynamic assessment. Due to the complexity and multiple factors involved, it has been proposed that artificial intelligence (AI) technology might be able to predict the risk of right ventricular failure post-LVAD implantation more accurately [67].…”

Section: Post-operative Temporary Mechanical Rv Supportmentioning

confidence: 99%

Advanced Heart Failure: Therapeutic Options and Challenges in the Evolving Field of Left Ventricular Assist Devices

Antonopoulos,

Bonios,

Dimopoulos

et al. 2024

JCDD

View full text Add to dashboard Cite

Heart Failure is a chronic and progressively deteriorating syndrome that has reached epidemic proportions worldwide. Improved outcomes have been achieved with novel drugs and devices. However, the number of patients refractory to conventional medical therapy is growing. These advanced heart failure patients suffer from severe symptoms and frequent hospitalizations and have a dismal prognosis, with a significant socioeconomic burden in health care systems. Patients in this group may be eligible for advanced heart failure therapies, including heart transplantation and chronic mechanical circulatory support with left ventricular assist devices (LVADs). Heart transplantation remains the treatment of choice for eligible candidates, but the number of transplants worldwide has reached a plateau and is limited by the shortage of donor organs and prolonged wait times. Therefore, LVADs have emerged as an effective and durable form of therapy, and they are currently being used as a bridge to heart transplant, destination lifetime therapy, and cardiac recovery in selected patients. Although this field is evolving rapidly, LVADs are not free of complications, making appropriate patient selection and management by experienced centers imperative for successful therapy. Here, we review current LVAD technology, indications for durable MCS therapy, and strategies for timely referral to advanced heart failure centers before irreversible end-organ abnormalities.

show abstract